rc48-adc
Locally Advanced and Metastatic Solid Tumors
BeiGeneantibody_drug_conjugatePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Locally Advanced and Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab BeiGene | Phase 1/2 | B |
FLUOROURACILUM BeiGene | Phase 2 | B |
Carboplatin Shanghai Runshi Pharmaceutical Technology Co., Ltd | Phase 1/2 | B |
Eloxatin BeiGene | Phase 2 | B |
ETOPOSIDE Shanghai Runshi Pharmaceutical Technology Co., Ltd | Phase 1/2 | B |
Ociperlimab BeiGene | Phase 1 | CC |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →